About Emerging Diseases Conference

With the tremendous success of the previous Emerging Diseases 2022, on October 17-18, 2022, we hereby invite all the participants from all over the globe to attend “14th International Conference on Emerging Infectious Diseases, September 25-26, 2023 Zurich, Switzerland.

We invite you to join us at the Emerging Diseases 2023 conference which will cover all the aspects of emerging infectious diseases, where you will be sure to have knowledge with scholars and experts from around the world for the paradigm of the infection diseases and latest research related to the this field. It will be a lifetime opportunity for high quality scientific program with session lectures, keynote talks, symposia, workshops, poster presentations, exhibition and different programs for participants from all across the globe.

The Emerging Diseases 2023 will focus on capturing new approaches and thinking, as well as the cornerstones of Emerging Infectious Diseases with healthcare epidemiology; antimicrobial resistance and stewardship; IPC in long-term care and non-clinical settings; education, training, and staff development; community engagement and patient care.

The conference will again offer a unique forum for participants to exchange knowledge and experience in the prevention of healthcare-associated infectious diseases around the world.

The most resonating topics will be addressed including: Infection diseases  in the context of the COVID-19 pandemic, antimicrobial resistance, catheter-related bloodstream infection, quality of patient care, advanced methods in hospital epidemiology research and early results of major clinical trials in the field, improving prevention strategies using various implementation tools as well as social media, telemedicine, and simulation models.

Emerging Diseases 2023 is a remarkable conference which brings together the international collaboration of scientists, Researchers, specialists from leading universities and research institutions making the conference a perfect platform to globalize experience, foster collaboration across industry and academia, and evaluate emerging technologies all around the world.

Target Audience:

Microbiologists
Bacteriologists
Virologists
Parasitologists
Mycologist
Pathologists
Pharmacists
Epidemiologists
Health care professionals
Research scholars
Infectious diseases associates and societies.
Laboratory technicians
Diagnostics companies
Drug manufacturing companies
Data management companies
Medical colleges
Infectious Diseases Researchers

Why to Attend?

Emerging Diseases 2023 is intended to honour prestigious award for talented Young researchers, Scientists, Young Investigators, Post-Graduate students, Post-doctoral fellows, Trainees, Junior faculty in recognition of their outstanding contribution towards the conference theme. The Young Scientist Awards make every effort in providing a strong professional development opportunity for early career academicians by meeting experts to exchange and share their experiences on all aspects of Infectious Diseases.

Young Research’s Awards at Emerging Diseases 2023 for the Nomination:

Young Researcher Forum - Outstanding Masters/Ph.D./Post Doctorate thesis work Presentation and only 25 presentations acceptable at the Emerging Diseases 2023.

YRF Registration Benefits:

Young Scientist Award recognition certificate and memento to the winners

Emerging Diseases 2022 provides best Platform for your research through oral presentations.

Learn about career improvement with all the latest technologies by networking.

Provide an opportunity for research interaction and established senior investigators across the globe in the field of Infectious Diseases.

It’s a great privilege for young researchers to learn about the research areas for expanding their research knowledge.

Emerging Diseases 2023 conference is giving a worldwide stage to the researchers who are contributing in the field of emerging infectious diseases. World-eminent speakers, guest of honours, and the most up to date upgrades are particular components of this get-together and with individuals from around the globe concentrated on finding out about uncommon illnesses and its advances; An expanding number of distinguished methods makes it important to complete propelled research here of irresistible sicknesses. Emerging Diseases 2023 provides you the forum to conduct presentations, disseminate data, B2B meetings, meet with potential scientists, trade learning on late improvements and make an unmistakable imprint by invigorating development at this event

Sessions

Track 1: Case Studies of Various Emerging Diseases

An emerging infectious disease  (EID) is a contagious disease whose occurrence has boosted in the last 50 years and chances are there that it could increase in the coming future. Emerging infections account for at least 15% of all human pathogens. EIDs are caused by freshly identified strains that may have emerged from a known infection or transferred to a new community or to a field undergoing conserves metamorphosis, or emerging infections. Of thriving concern are adverse synergistic communication between emerging diseases and other infectious and non-infectious conditions ruling to the evolution of unusual syndemics. Many emerging diseases are zoonotic or synoptic - an animal receptacle incubates the organism, with only random conveyance into human populations. Infectious Diseases square amplitude ataxia caused by micro-organism such as viruses, fungi or parasites. Infectious diseases is also, foodborne, vector borne, air borne in  related as  further more  in plants and animals. They essentially affirm on the pathological approach of the microorganism and their therapeutic amplifications, synthesis of division of particularly clinical and diagnostic biology that deals with the cure endurance of the contagious diseases. It exemplifies associate degree progressively mandatory for human pessimism and fatality reason throughout the map.

Track 2: Classification of Emerging Diseases

The type diseases become extremely crucial in the assortment of statistics on reasons behind the illness (morbidity) and causes of death (mortality). It is very important to know the kinds of ailments and disease that are common in an area and how their prevalence rates differ with time to time. Classification of disease has helped to detect an important, frequently causal, relationship.

Track 3: Diagnosis and Prevention

Diagnosis of disease involves determining an infectious pathogen either directly or indirectly. In practice, most are diagnosed by their clinical presentation and are treated without the expertise of that causative agent. Outcome of the cause of the disease are based upon the likelihood that a patient came in contact with a specific agent, the presence of a pathogen in a community, and other epidemiological considerations. When sufficient efforts are given, the infectious agents can be specifically examined.

Track 4: Rare Infectious Diseases

Rare diseases are those medical anomalies, which affect a very least number of the population. They are defined by a wide variety of disorders and syndrome that differs not only from disease to disease but also from person to person suffering from these diseases. About 70% of these disorders are recognized by genetic origins while the others are the result of infections, allergies and environmental outcomes.

Track 5: Infectious Diseases in children

Pediatric infectious diseases are the contagious diseases which are caused in children of different age groups. Pediatric infectious diseases consultant takes care of the infections occurring in children and the curing approaches vary for children from adults. Spreading of diseases can be through direct contact like touching and indirect contact with the infected person. Droplet transmission is very common. Airborne spreading occurs when germs stay in the air and are carried around on air current.

Track 6: Maternal Infectious Diseases

After the birth of the infants, they receive intestinal microflora from their mother’s microbiota. An infant’s indigenous floras differ by mode of delivery and are shaped by environment, genetics, and the mode of feeding. Breast milk affects the infant’s intestinal microflora by contributing maternal skin organisms along with the ones that nurture some microbes and offer defense from others. While breast milk can be a source of maternally derived commensal and pathogenic microbes, there are very few maternal infectious diseases for which the cessation or interruption of breastfeeding is indicated. When a nursing a mother presents the symptoms of an infectious disease and she has already exposed her baby to the pathogen. Cessation of breastfeeding does not prevent exposure, and rather decrease the infant’s protection that comes through specific maternal antibodies and other protective factors found in human milk. Therefore, common maternal bacterial, fungal and viral infections in which the mother’s health is not compromised are not contraindications to breastfeeding.

Track 7: Infectious Diseases in Animals

Infectious diseases of animals are a major hazard to earthly animal health and welfare and their effective control is necessary for agronomic health, for defending and procuring national and international food supplies and for mitigating rural poverty in developing countries. Some catastrophic livestock diseases are regional in many parts of the world and threats from old and new pathogens continue to rise, with changes to worldwide climate, agricultural approaches and anthropology presenting conditions that are especially supportive for the spread of arthropod-borne diseases into new geographical fields. Zoonotic or phonetic infections that are transmissible either directly or indirectly between animals and humans are on the increase and pose serious additional risks to human health and the recent pandemic status of new influenza A (H1N1) is a topical illustration of the challenge presented by zoonotic viruses.

Track 8: Gastrointestinal Infections

Gastrointestinal infections are bacterial, viral or parasitic infections that leads to gastroenteritis, which is an inflammation of the gastrointestinal tract, which involves both the stomach and the small intestine. Symptoms of such anomalies are diarrhea, vomiting, and abdominal pain. Dehydration is the main outcome of gastrointestinal infections, so rehydration is important, but most gastrointestinal infections are self-limited and resolve within a few days. However, in a healthcare setting and in specific populations (newborns/infants, immunocompromized patients or elderly populations), they are potentially serious. Rapid diagnosis, appropriate treatment and infection control steps are eventually important in these contexts.

Track 9: Dermatological Infectious Diseases

Skin infections often begin as minute, red bumps, which slowly increase in size. Some bacterial infections are mild and can easily be treated with antibiotics, but some of them require an oral antibiotic. The symptoms of a skin disorders differ depending on its type. Common symptoms include redness of the skin and a rash. One can also experience common symptoms like itching, pain, and tenderness. Skin infections can spread beyond the skin and seep into the bloodstream. This can be life threatening.

Track 10: Zoonotic Ailments

Zoonotic diseases are often called as Zoonosis. This type of ailments transfers from an animal or insect to a human being. Some of them do not affect the animal but will sicken a human. Zoonotic diseases can range from minor short-term illness to a major life-changing illness. Certain ones can even be lethal.

Track 11: Air borne, Vector Borne and Food Borne Infections

Consumption of contaminated foods or beverages generally leads to foodborne diseases. The initial symptoms may occur within minutes to weeks and regularly occur like flu-like symptoms. Symptoms of infected person are vomiting, nausea, diarrhea or fever as the symptoms are flu-like many people may not recognize that the sickness is caused by bacteria or other contaminant in food. Airborne diseases are caused by pathogens that can be transmitted via air. When an infected person sneezes, coughs or talks, spewing nasal and throat secretions into the air airborne diseases can be usually spread. Tuberculosis (TB) is primarily an airborne disease which is caused by the bacteria Mycobacterium tuberculosis, which is spread person-to-person via air. This bacterium mainly affects the lungs, but may adversely affect other organs.

Track 12: Antimicrobial Agents

An antimicrobial is a substance which kills microorganisms or halts their growth. Antimicrobial medicines can be classified according to the microorganisms they act primarily against them. For instance, antibiotics are used against bacteria on the other hand antifungals are used against fungi. They can also be classified according to their function. Agents that kill microbes are called microbicidal, while the one which only inhibits their growth are termed as biostatic.

Track 13: Pathogenic and Biochemistry of the Pathogens

Pathogenicity refers to the ability of an organism to cause infections. This capability represents a genetic component of the pathogen and the apparent damage done to the host is a property of the host-pathogen interactions. The commensals and opportunistic pathogens lack this inherent ability to cause disease.

Track 14: Current Research and Advancements

Chemicals, drugs or other substances which are used to treat infectious disease can include either antibacterial or antiviral agents. Along with the discovery, development and clinical use of antibacterial drugs, the mortality from infections has been eventually reduced in past few years. However, antibiotic resistant pathogens have accelerated emergence as a consequence of widespread and injudicious use of antimicrobial drugs, which results in a serious threat to public health.

Track 15: Occupational Health and Safety

Occupational health is an integrative field that is concerned with the health, safety and welfare of people who are at work. It mainly focuses on primary prevention of hazards and also deals with all aspects of health and safety in work place. The main motto of this is to keep an eye and promote worker’s health by checking their working capacity and developing a suitable work place where working values is to support health and safety at work.

Track 16: Plant Pathology and Disease Control

This field is also known as plant pathology, which is a scientific study of diseases in plants caused by pathogens or environmental conditions. The organisms that cause infectious disease in plants include oomycetes, fungi, bacteria, viruses, viroids, virus-like organisms, phytoplasmas, protozoa, nematodes and parasitic plants. Not included are ectoparasites like mites, vertebrate, insects or other pests that affect plant health by consumption of plant tissues. It also includes the study of disease cycles, economic impact, plant disease epidemiology, plant disease resistance, pathogen identification, disease etiology, how plant diseases affect humans and animals, pathosystem genetics, and management of plant diseases.

Track 17: Pharmacology and Infectious Diseases

Pharmacology is a recently developed wing of biology which is concerned with the study of drug action and drug can be broadly defined as any man-made, natural, or molecule which exerts a biochemical or physiological effect on the cell, tissue, organ, or organism. More prominently, it is the study of the interactions which occur between a living organism and chemicals that affect normal or abnormal biochemical function. Pharmaceuticals are the one which have medicinal properties.

Track 18: Public Health Practices

The Public Health Practice concentration is organized toward people who are able to enlist in courses that utilize amalgam of on-line, video conference, and in person teaching modalities.  Students selecting the public health practice program should hold an academic background in a public health related field and/or experience working or volunteering within at least one public health program. Work includes subject matter in the crux areas of public health: Epidemiology, Biostatistics, Environmental and occupational health, Public health policy and management, Socio-cultural and behavioral aspects of public health.

Relevant Conferences and Societies

Relevant Conferences:

Emerging Infectious Diseases Conferences | Infections Diseases Europe Meetings | Emerging Diseases Asia 2021 Meetings | Infectious Diseases Conference USA 2021 Meetings

17th World Congress on Infection Prevention and Control June 07-08, 2021 Webinar; 6th International Conference on Bacteriology July 12-13, 2021 Webinar; 9th World Congress on Control and Prevention of HIV/AIDS, STDs & STIs August 23-24, 2021 Vienna, Austria; 6th International Conference on Digestive and Metabolic Diseases September 06-07, 2021 Berlin, Germany; 11th World Congress on Rare Diseases and Orphan Drugs September 06-07, 2021 Berlin, Germany; 13th Euro-Global Conference on Infectious Diseases October 11-12, 2021 London, UK ; 12th International Conference on Emerging Infectious Diseases October 22-23, 2021 Rome, Italy.

Related Societies:

USA: Infectious Diseases Society of America, National Foundation of Infectious Disease, National AIDS Commission, HIV Medicine Association, International Society for Infectious Diseases, American Society of Microbiology, Victorian Infection & Immunity Network and American Association of Immunologists.

Europe: European Society of Clinical Microbiology and Infectious Diseases, British Infection Association, European AIDS Clinical, UNAIDS, British Society for Immunology, National Institute of Allergy and Infectious Diseases, European Federation of Immunological Societies, European Aids Clinical Society and Scandinavian Society for Immunology.

Asia Pacific: Clinical Infectious Diseases Society India, IASSTD & AIDS, National AIDS Control Organization, Australasian Society for Infectious Diseases, Australasian Society for Immunology, Chinese Society for Immunology and International AIDS Society.

Market Analysis

This International two day conference will provide practical evidence based strategies to engage your workforce and reduce the spread of acute healthcare associated infections. Emerging Diseases 2023 is to promote the health care perspectives which include plenary speeches, roundtable discussions, symposiums, abstracts, and workshops on Emerging Infectious Diseases and Control risks. The goal is to bring together a multidisciplinary group to identify important issues relating to diseases which is emerging in Russia, Europe, United States, and Asia Pacific, Middle East and other parts of the world. Over 500 scientists, clinicians, nurses, patients, government officials, and representatives from pharmaceutical companies will participate. This summary provides the recommendations from the conference that will be used to develop an action plan against infectious diseases which is lethal to the world. It also comprises of actions proposed by plenary speakers, roundtable faculty and students, conference participants.

Importance and Scope: An emerging infectious diseases meeting puts together various practices which when used appropriately restrict the spread of infection. The awareness is required to prevent the transmission of communicable diseases in all health care settings. The notion of the conference demands a basic understanding of the epidemiology of diseases; the importance of establishing prevention measures and bundles during hospital renovation works to preserve the patient from environment-borne infections. This peer is also imperative for health care administrators to ensure implementation of the infection control program in health care facilities.

It also causes for the significant patient safety issue, and can also be an Occupational Health and Safety issue. A well functioned awareness program helps to minimize the risks for patients. Each health care worker needs to understand their role in public health practice, integrate it into daily activities, and articulate this role to others.

Why Zurich, Switzerland?

Zürich is the largest city in Switzerland and the capital of the canton of Zürich. It is located in north-central Switzerland, at the northwestern tip of Lake Zürich. As of January 2020, the municipality has 434,335 inhabitants, the urban area 1.315 million (2009), and the Zürich metropolitan area 1.83 million (2011). Zürich is a hub for railways, roads, and air traffic. Both Zurich Airport and Zürich's main railway station are the largest and busiest in the country.

Permanently settled for over 2,000 years, Zürich was founded by the Romans, who called it Turicum. However, early settlements have been found dating back more than 6,400 years (although this only indicates human presence in the area and not the presence of a town that early).During the Middle Ages, Zürich gained the independent and privileged status of imperial immediacy and, in 1519, became a primary center of the Protestant Reformation in Europe under the leadership of Huldrych Zwingli.

Members Associated with Emerging Infectious Diseases Research: The mission of the Emerging Diseases 2022 conference in Health Care initiative was to assist in reducing dissemination of infections associated with healthcare, by assisting with the assessment, planning, implementation and evaluation of national infection control policies. The ultimate goal is to endorse quality promotion of health care which is safe for patients, health care workers, others in the health care setting and the environment, in the Infectious Diseases field.

Hospitals Associated with Emerging Infectious Diseases Research: Healthcare-associated infections (HAI) are a threat to patient safety. CDC provides national leadership in surveillance, outbreak investigations, laboratory research, and prevention of healthcare-associated infections. CDC uses knowledge gained through these activities to detect infections and develop new strategies to prevent healthcare-associated infections. Public health action by CDC and other healthcare partners has led to improvements in clinical practice, medical procedures, and the ongoing development of evidence-based infection control guidance and prevention successes.

Major Infectious Diseases Research Associations around the Globe:

British Infection Association

Infectious Disease Society of America

Infectious Diseases Research Network

European Society for Clinical Microbiology and Infectious Diseases

British Society for Antimicrobial Chemotherapy

Society for General Microbiology

British HIV Association

The Hospital Infection Society

Infection Prevention Society

The Royal Society of Tropical Medicine and Hygiene

UK Clinical Virology Network

World Health Organization

Royal Society for Public Health

Health Protection Scotland

The Society of Health care Epidemiology of America

Centers for Disease Control and Prevention

Asia Pacific Society of Infection Control

Infection Control Association

Infection Prevention & Control - American Nurses Association

Infection prevention and Control Canada

The Infection Control Nurses Association

Infection Control - California Hospital Association

Infection Control Association of Zimbabwe

International Federation of Infection Control

Texas Society of Infection Control & Prevention

Philippine Hospital Infection Control Society

Healthcare Infection Society

Infection Control Association of NSW

Major Universities on Infection Prevention Research

Anahuac University North Campus, Mexico

Australian National University, Australia

Benha University, Egypt

Birmingham City University, UK

Center for Clinical Pharmacology, Belgium

Charles Darwin University Casoria Australia

Columbia University Medical Center, United States

Columbia University, USA

Curtin University Bentley, Australia

Dar Al Uloom University, Saudi Arabia

Duke University, USA

Emory University, USA

GMEC, The Global Medical Excellence Cluster

Guangzhou Medical University, China

Guangzhou Medical University, China

Harvard University, United States

Harvard University, USA

Imperial College London, United Kingdom

Infection Control University

Iqbal Chest Centre, Bangladesh

John Hopkins University, USA

Johns Hopkins University, United States

Karolinska University, Sweden

Kindai University, Japan

King Saud Bin Abdulaziz University, Saudi Arabia

King's College London, UK

Kumamoto University, Japan

Linnaeus University, Sweden

Macquarie University, Australia

Mayo Clinic College of Medicine, USA

McGill university   Montréal, Canada

McMaster University, Canada

Medi7 Bentleigh, Australia

Murdoch University   Murdoch, Australia

National Institutes of Health, USA

Newcastle University, Australia

Northwestern University, Qatar

Osaka University, Japan

Oxford University, UK

Philip Morris International R&D, Switzerland

Pompeu Fabra University, Spain

Queen Mary University, UK

Radboud University Medical Center, Netherlands

Rare Genomics Institute, USA

Research Institute of Hospital del Mar, Spain

Samsung Medical Center, South Korea

St George’s University of London, UK

St. George Hospital, Australia

Stanford University, USA

Tasmanian Health Service, Australia

The Chest & Heart Association of Bangladesh, Bangladesh

The Fourth Hospital of Harbin Medical University, China

The Jikei University School of Medicine, Japan

The University of Newcastle, Australia

Tufts university, United States

United Hospital, Bangladesh

University College London, UK

University of British Columbia, Canada

University of Buffalo, United States

University of California Los Angeles, United States

University of California, USA

University of Cambridge, USA

University of Canberra Bruce, Australia

University of Celiac Disease Center, USA

University of Chicago Medicine, USA

University of Colorado, USA

University of Groningen, Netherlands

University of Lincoln, UK

University of London Imperial College Of Science Technology And Medicine, UK

University of Maastricht, Netherlands

University of Maryland Medical Center, Australia

University of Maryland Medical Center, United States

University Of Melbourne, Australia

University Of Minnesota, United States

University of Newcastle, Australia

University of Pennsylvania, USA

University of Pittsburgh Study

University of Pittsburgh, USA

University of Queensland, Australia

University of Tasmania, Australia

University of Toronto, Canada

University of Valencia, Spain

University of Washington, USA

University of Washington, USA

University of Zurich, Switzerland

University-of-the-sunshine-coast, Australia

Weill Cornell Medical College, Qatar

Wits University, South Africa

Yale University School of Medicine, USA

Yonsei University, South Korea

Major Companies Associated with Infection Prevention Research

Abbott Laboratories, UK

Actavis, USA

Aegerion Pharmaceuticals, Japan

Alexion Pharmaceuticals Inc, Switzerland

Almirall, Spain

Amgen, USA

Amicus Therapeutics, USA

Amphastar Pharmaceuticals, Inc

Araim Pharmaceuticals

Astellas Pharma US

AstraZeneca, Switzerland

AstraZeneca, UK

Baxter International Deerfield

Bayer HealthCare, Germany

Bayer, Germany

Beacon Pharmaceuticals, Bangladesh

Biotie Therapies Corp, Finland

Bioxyne Limited, Australia

Boehringer Ingelheim, Germany

Celgene, Switzerland

Centrapharm Ltd, UK

Chiesi Pharmaceutical, Italy

Cohero Health, USA

Daiichi Sankyo Europe, Germany

Daiichi Sankyo, Japan

Dohmen Life Science

European Medicines Agency

Forest Laboratories, USA

Gecko Health, USA

Generics (UK) Ltd, UK

Genus Oncology Vernon Hills, USA

Genzyme, USA

Gilead sciences, USA

GlaxoSmithKline, UK

Global Data, UK

Gsk, London

Hormosan Pharma, Germany

Ikris Pharma Network Pvt Ltd, India

Kissei Pharmaceutical Co., Ltd, Japan

Kyowa Hakko Kirin Co. Ltd, Japan

Lallemand Pharma, Switzerland

Marathon Pharmaceuticals

Merck & Co, USA

Millennium Pharmaceuticals

Napp Pharmaceuticals Ltd, UK

Novartis, Switzerland

NPS Pharmaceuticals

Octapharma, USA

Onyx Pharmaceuticals, USA

Otsuka Holdings Co., Ltd, Japan

Panmira Pharmaceuticals, LLC, USA

Pearl Therapeutics, Inc

Pfizer, USA

PharmaMar, USA

Prosensa, Netherlands

PT Boehringer Ingelheim, Indonesia

Queensland Respiratory Laboratory Pty. Ltd, Australia

Ranbaxy Laboratories Limited

Raptor Therapeutics

Roche, Switzerland

Sanofi, France

Sarepta Therapeutics, USA

Sigma-Tau Pharmaceuticals, Italy

Sunovion Pharmaceuticals, USA

Swedish Orphan Biovitrum AB, Sweden

Takeda, Japan

TriStem Corp Ltd, UK

Vertex Pharmaceuticals, USA

ViroPharma

ViroPharma, USA

Visionary Pharmaceuticals, Inc, USA

Yungjin Pharm Ind. Co., Ltd, South Korea

Market Research on Emerging Diseases: The global infectious disease market size was valued at USD 46.88 billion in 2019 and is projected to grow at a CAGR of 6.6% during the forecast period. Rising prevalence of infectious ailments, increasing expenditure to boost the penetration rate of treatments of these diseases, rising initiatives for creating awareness about treatments & diagnosis of these conditions, and increasing clinical trial studies for development of new drugs are likely to be the factors responsible for growth of this market.  In 2018, the HIV segment held the largest share i.e., 45.9% of the market. Increasing prevalence of HIV, rising funding activities for patients suffering from HIV, increasing supply of free HIV self-test kits in African countries, and rising awareness campaigns are the key factors responsible for the largest share held by this segment. In addition, WHO aims to test 90% and treat 80% of the people suffering from HBV and HCV by 2025, through its Global Health Sector Strategy on viral hepatitis, which is further expected to contribute to the growth of this segment.

For more details please visit: https://emerging-diseases.infectiousconferences.com/